CY1106971T1 - Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης - Google Patents

Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης

Info

Publication number
CY1106971T1
CY1106971T1 CY20071101406T CY071101406T CY1106971T1 CY 1106971 T1 CY1106971 T1 CY 1106971T1 CY 20071101406 T CY20071101406 T CY 20071101406T CY 071101406 T CY071101406 T CY 071101406T CY 1106971 T1 CY1106971 T1 CY 1106971T1
Authority
CY
Cyprus
Prior art keywords
agonists
peptide
tzd
glp
insulin
Prior art date
Application number
CY20071101406T
Other languages
English (en)
Inventor
Fatima Emitsel Yakubu-Madus
Laurence E Stramm
William T Johnson
Louis Vignati
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22488329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106971(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1106971T1 publication Critical patent/CY1106971T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Θειαζολιδινοδιόνη (ΤΖD) και φαρμακολογικώς δραστικά παράγωγα αυτής μπορεί να χρησιμοποιηθούν σε συνδυασμό με αγωνιστές πεπτιδίου-1 που ομοιάζει με γλυκογόνο (GLΡ-1), για να θεραπεύεται μη-ινσουλινο εξαρτώμενος διαβήτης, προαιρετικά με άλλες θεραπείες, με βελτίωση γλυκαιμικού ελέγχου, ενώ ελαχιστοποιούνται παρενέργειες, όπως καρδιακή υπερτροφία και αυξημένη γλυκόζη πλάσματος κατάστασης χορτάτου, που συνδυάζονται τόσο με ΤZD όσο και με GLΡ-1 μονοθεραπείες. Έτσι, η συνχορήγηση TΖD και GLΡ-1 βοηθά να ρυθμίζεται η ομοιόσταση γλυκόζης σε διαβητικούς ασθενείς Τύπου II.
CY20071101406T 1999-06-21 2007-11-01 Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης CY1106971T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13979499P 1999-06-21 1999-06-21
EP00938173A EP1133312B8 (en) 1999-06-21 2000-06-06 Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes

Publications (1)

Publication Number Publication Date
CY1106971T1 true CY1106971T1 (el) 2012-09-26

Family

ID=22488329

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101406T CY1106971T1 (el) 1999-06-21 2007-11-01 Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης

Country Status (12)

Country Link
US (3) US6660716B1 (el)
EP (2) EP1849475A1 (el)
AT (1) ATE372782T1 (el)
AU (1) AU5325200A (el)
CA (1) CA2349865C (el)
CY (1) CY1106971T1 (el)
DE (1) DE60036367T2 (el)
DK (1) DK1133312T3 (el)
ES (1) ES2291210T3 (el)
PT (1) PT1133312E (el)
SI (1) SI1133312T1 (el)
WO (1) WO2000078333A2 (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
PT1808438E (pt) 1999-06-29 2015-01-14 Mannkind Corp Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
CA2430934C (en) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
AU2002235731A1 (en) * 2001-03-07 2002-09-19 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
AU2002332054B2 (en) 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
FR2832064A1 (fr) * 2001-11-13 2003-05-16 Lipha Composition pharmaceutique comprenant une glitazone et un derive de thiazolidinedione et son utilisation pour traiter le diabete
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
DE60209824T2 (de) * 2001-12-21 2006-10-19 Smithkline Beecham Corp. Dosierschema für ppar-gamma-aktivatoren
WO2003057235A2 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
EP1688148A1 (en) * 2002-12-03 2006-08-09 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1577673B1 (en) * 2004-03-15 2008-07-30 F. Hoffmann-La Roche Ag The use of BNP-type peptides and ANP-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload
DE602005014969D1 (de) 2004-04-23 2009-07-30 Conjuchem Biotechnologies Inc Verfahren zur aufreinigung von albumin-konjugaten
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
WO2007115131A2 (en) * 2006-03-29 2007-10-11 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including other ingredient(s)
DK1937219T3 (en) 2005-09-14 2016-02-15 Mannkind Corp A method for drug formulation based on increasing the affinity of the crystalline surfaces of the microparticle of active principles
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
IN2015DN00888A (el) 2006-02-22 2015-07-10 Mannkind Corp
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
PL2107905T3 (pl) * 2007-02-01 2011-04-29 Takeda Pharmaceuticals Co Stały preparat zawierający alogliptynę i pioglitazon
EP2954893A1 (en) * 2007-10-24 2015-12-16 MannKind Corporation An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
KR20130123470A (ko) * 2007-10-24 2013-11-12 맨카인드 코포레이션 활성제의 전달
WO2009075859A2 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
JP5382879B2 (ja) * 2007-12-13 2014-01-08 国立大学法人九州大学 薬物含有ナノ粒子
KR101933816B1 (ko) 2008-06-13 2019-03-29 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
WO2010141938A1 (en) * 2009-06-05 2010-12-09 Veroscience, Llc Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
MX360304B (es) * 2012-05-17 2018-10-29 Vtv Therapeutics Llc Composiciones de activador de glucocinasa para el tratamiento de la diabetes.
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
ES2624294T3 (es) 2012-07-12 2017-07-13 Mannkind Corporation Sistemas de suministro de fármacos en polvo seco
US20140178456A1 (en) * 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349352A (en) * 1980-08-14 1982-09-14 Rockefeller University Test for glucosylated hemoglobin and other glucosylated proteins
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
JPH10511365A (ja) * 1994-12-23 1998-11-04 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１組成物
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
CA2329004C (en) * 1998-06-30 2009-04-14 Takeda Chemical Industries, Ltd. Combination of insulin sensitizer with anorectic for treating or preventing diabetes

Also Published As

Publication number Publication date
SI1133312T1 (sl) 2008-02-29
US20040127414A1 (en) 2004-07-01
EP1133312B8 (en) 2007-10-17
DK1133312T3 (da) 2008-01-02
DE60036367D1 (de) 2007-10-25
CA2349865C (en) 2014-08-19
ATE372782T1 (de) 2007-09-15
EP1849475A1 (en) 2007-10-31
CA2349865A1 (en) 2000-12-28
WO2000078333A2 (en) 2000-12-28
EP1133312A2 (en) 2001-09-19
US6660716B1 (en) 2003-12-09
USRE40876E1 (en) 2009-08-18
WO2000078333A3 (en) 2001-07-12
EP1133312B1 (en) 2007-09-12
ES2291210T3 (es) 2008-03-01
PT1133312E (pt) 2007-11-30
US7223728B2 (en) 2007-05-29
DE60036367T2 (de) 2008-05-29
AU5325200A (en) 2001-01-09

Similar Documents

Publication Publication Date Title
CY1106971T1 (el) Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης
Dungan et al. A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)
Urva et al. The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
Inzucchi et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?
Nauck Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
Singh Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
Barnett et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
DK1181043T3 (da) Anvendelse af exendiner og agonister dertil til behandling af svangerskabsdiabetes mellitus
Balkan et al. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms
Bolli et al. Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus
Al-Kuraishy et al. Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: the intriguing effect
WO2006000567A3 (en) Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
DE69942307D1 (de) N-terminal veränderte glp-1 abkömmlinge
Sanyal et al. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
RU2008110504A (ru) Способы лечения диабета и снижения массы тела
NZ514610A (en) Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
Chaudhuri et al. Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators
NO20015932L (no) Fremgangsmåte til å behandle diabetes
Meier et al. Impact of insulin glargine and lixisenatide on β‐cell function in patients with type 2 diabetes mellitus: A randomized open‐label study
Davidson Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
NZ602583A (en) Methods of using diacerein as an adjunctive therapy for diabetes
WO2007076505A3 (en) Transferrin and transferrin-based compositions for diabetes treatment
Kitazawa et al. Combination therapy of glucagon‐like peptide‐1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomy
EA202192296A1 (ru) Терапевтическое применение дулаглутида